Jeff Boden, Ph.D.

Jeff Boden, Ph.D.

Dr. Boden leads all Nonproprietary (INN/USAN) naming projects for the organization.  He is an expert in the policies and procedures of the INN Expert Group and USAN Council and, in total, has submitted over 1000 nonproprietary naming applications; more than anyone in the world.  Prior to joining Kaleio he served as Vice President of the Nonproprietary Naming Division at Brand Institute and led all related operations of the company from their Miami headquarters.  In addition to his work in Nonproprietary Naming, Dr. Boden has previously held positions in pharmaceutical R&D for Alkermes, Integene, and Goodwin Biotech.  He earned his BA in Biology from the College of the Holy Cross and has a PhD in Cancer Biology from the University of Miami.

ARTICLES

• How Drugs Are Named
• A Comparison Of Bamlanivimab Versus Bamlanivimab-Etesevimab (contributor)
• How Ibrexafungerp Got Its Name
• How Comirnaty Was Named: The Story Behind Pfizer’s Oddly Named mRNA Vaccine
• Molnupiravir – The New COVID Antiviral Named After Thor’s Hammer